[go: up one dir, main page]

EP0431064A4 - Recombinant vaccinia virus for prevention of disease caused by flavivirus - Google Patents

Recombinant vaccinia virus for prevention of disease caused by flavivirus

Info

Publication number
EP0431064A4
EP0431064A4 EP19890910317 EP89910317A EP0431064A4 EP 0431064 A4 EP0431064 A4 EP 0431064A4 EP 19890910317 EP19890910317 EP 19890910317 EP 89910317 A EP89910317 A EP 89910317A EP 0431064 A4 EP0431064 A4 EP 0431064A4
Authority
EP
European Patent Office
Prior art keywords
flavivirus
prevention
vaccinia virus
disease caused
recombinant vaccinia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19890910317
Other versions
EP0431064A1 (en
Inventor
Ching-Juh Lai
Michael P. Bray
Bangti Zhao
Robert M. Chanock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Commerce
US Department of Health and Human Services
Original Assignee
United States Department of Commerce
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of Commerce, US Department of Health and Human Services filed Critical United States Department of Commerce
Publication of EP0431064A1 publication Critical patent/EP0431064A1/en
Publication of EP0431064A4 publication Critical patent/EP0431064A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP19890910317 1988-08-20 1989-08-21 Recombinant vaccinia virus for prevention of disease caused by flavivirus Withdrawn EP0431064A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23920588A 1988-08-20 1988-08-20
US239205 1988-08-20

Publications (2)

Publication Number Publication Date
EP0431064A1 EP0431064A1 (en) 1991-06-12
EP0431064A4 true EP0431064A4 (en) 1991-11-13

Family

ID=22901085

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19890910317 Withdrawn EP0431064A4 (en) 1988-08-20 1989-08-21 Recombinant vaccinia virus for prevention of disease caused by flavivirus

Country Status (5)

Country Link
EP (1) EP0431064A4 (en)
JP (1) JPH03503364A (en)
AU (1) AU624863B2 (en)
IL (1) IL91304A0 (en)
WO (1) WO1990001946A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767449B1 (en) 1981-12-24 2010-08-03 Health Research Incorporated Methods using modified vaccinia virus
US6676936B1 (en) 1988-07-14 2004-01-13 The United States Of America As Represented By The Department Of Health And Human Services. Chimeric and/or growth-restricted flaviviruses
US6184024B1 (en) 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
FI902814A0 (en) * 1989-06-06 1990-06-05 Immuno Ag PROTEINER, VACCIN OCH NUKLEINSYROR.
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
EP1605047B1 (en) * 1991-09-19 2009-09-16 The United States of America, as represented by the Secretary Department of Health and Human Services Chimeric and/or growth-restricted flaviviruses
US6117640A (en) * 1995-05-02 2000-09-12 The United States Of America As Represented By The Secretary Of The Army Recombinant vaccine made in E. coli against dengue virus
DK0836482T3 (en) * 1995-05-24 2003-02-17 Hawaii Biotech Group Subunit vaccine against flavivirus infection
ID19548A (en) 1996-09-24 1998-07-23 Bavarian Nordic Res Inst As RECOMBINED MVA VIRUSES EXPRESSING FEATURES ANTIGENS AND FEVER USING THEMS IN VACCINES
JP4504464B2 (en) * 1997-02-28 2010-07-14 サノフィ パスツール バイオロジクス カンパニー Chimeric flavivirus vaccine
BR9910830A (en) * 1998-06-04 2001-02-13 Us Gov Health & Human Serv Nucleic acid vaccines to prevent flavivirus infection
US7227011B2 (en) 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
JP4656794B2 (en) 2000-02-16 2011-03-23 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ，センターズ フォー Non-toxic immunogenic flavivirus chimera
EP2345665A3 (en) 2001-12-04 2012-02-15 Bavarian Nordic A/S Flavivirus NS1 subunit vaccine
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
PE20211814A1 (en) 2013-03-15 2021-09-14 Takeda Vaccines Inc COMPOSITIONS AND METHODS OF CHEMERICAL CONSTRUCTION OF DENGUE VIRUS IN VACCINES
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
CA3111332A1 (en) 2018-09-05 2020-03-12 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
JP7554423B2 (en) * 2019-03-14 2024-09-20 公益財団法人東京都医学総合研究所 Dengue vaccine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2620459A1 (en) * 1987-09-16 1989-03-17 Nippon Zeon Co RECOMBINANT VACCINE VIRUS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2620459A1 (en) * 1987-09-16 1989-03-17 Nippon Zeon Co RECOMBINANT VACCINE VIRUS

Also Published As

Publication number Publication date
AU4206489A (en) 1990-03-23
AU624863B2 (en) 1992-06-25
EP0431064A1 (en) 1991-06-12
WO1990001946A1 (en) 1990-03-08
JPH03503364A (en) 1991-08-01
IL91304A0 (en) 1990-03-19

Similar Documents

Publication Publication Date Title
EP0431064A4 (en) Recombinant vaccinia virus for prevention of disease caused by flavivirus
IL87581A0 (en) Recombinant avipox virus
GB8821528D0 (en) Recombinant vaccinia virus
ATA902590A (en) RECOMBINANT SMALL VIRUS
DK603888D0 (en) RECOMBINANT VIRUS
IT1239987B (en) SPECTRUM SELECTION SYSTEM OF INFECTIVITY OF RECOMBINANT POXVIRUS
EP0258289A4 (en) Peptide analogs
NO892251D0 (en) PROCEDURE FOR THE PREPARATION OF COCOCOIDOSE VACCINE BY RECOMBINANT TECHNIQUES.
ZM9387A1 (en) Treatment of diseases caused by viruses
HU912526D0 (en) Recombinant marek-type disease virus
DK197989D0 (en) peptide analogs
IL93367A0 (en) Fine-grained microstructure processor
IL89601A0 (en) Expression vectors containing a recombinant vaccinia virus
EP0450100A4 (en) Physiologically active peptide
GB8716953D0 (en) Restricting movement of lever
GB8916391D0 (en) Preparation of polyacetals
ITMI931371A0 (en) PROCEDURE FOR THE PREPARATION OF ERDOSTEINE
ZA908935B (en) Prevention of glycoprotein enveloped virus infectivity by pyridinyloxazole-2-ones
GB8819884D0 (en) Syringe for preparation of casting patterns
GB8914680D0 (en) Prevention of aid virus
ITMI910861A0 (en) IMPROVED PROCEDURE FOR THE PREPARATION OF MATURE POLYPEPTIDES
IL84541A0 (en) Pharmaceutical composition for treating a disease caused by virus
IE870898L (en) Recombinant vaccinia virus.
IE883428L (en) Dsrn based prevention of viral escape
IE892593L (en) Treatment of virus diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19910219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CHANOCK, ROBERT, M.

Inventor name: BRAY, MICHAEL, P.

Inventor name: LAI, CHING-JUH

Inventor name: ZHAO, BANGTI

A4 Supplementary search report drawn up and despatched

Effective date: 19910923

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19931116

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19940329